METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine targets tough cancers in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 12:04 UTC
-
New hope for advanced lung cancer: drug combo trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest and most effective dose and to see how well the combination works. About 69 particip…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New combo therapy aims to boost immune attack on tough lung cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PBF-1129 combined with the immunotherapy nivolumab in people with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. About 30 adults who have al…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New radiation technique aims to control brain metastases while protecting memory
Disease control Recruiting nowThis study tests a radiation method that targets the entire brain and spinal cord to kill cancer cells that have spread there, while avoiding a memory-related area called the hippocampus. It is for people with breast or lung cancer that has reached the fluid and tissues around th…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
New radiation approach targets cancer in brain and spine fluid
Disease control Recruiting nowThis study tests a type of radiation therapy (craniospinal irradiation) for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this treatment can help control the disease in the central nervous system.…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
Common painkiller may help immunotherapy fight lung cancer
Disease control Recruiting nowThis study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults with stage III or IV non-small cell lung cancer will re…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New drug combo targets tough lung cancer mutation
Disease control Recruiting nowThis study tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 37 adul…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for stubborn lung cancer: drug duo targets genetic mutation
Disease control Recruiting nowThis study tests a new drug combination (GT103 plus pembrolizumab) for people with advanced non-small cell lung cancer that has a specific genetic change called STK11 mutation. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth. About 28 adults …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug duo aims to boost immune attack on lung cancer
Disease control Recruiting nowThis study tests whether adding SX-682 to the immunotherapy drug pembrolizumab helps shrink tumors in people with advanced non-small cell lung cancer that has spread or returned. About 30 adults whose tumors have a certain protein (PD-L1) will receive both drugs. The goal is to s…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy aims to boost immune attack on lung cancer
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—in people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune sy…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo targets hard-to-treat lung cancer in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive the combinat…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug combo aims to control advanced lung cancer
Disease control Recruiting nowThis early-phase study tests a combination of two drugs, osimertinib and tegavivint, as the first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The main goal is to find the safest dose and see how well the drugs work togeth…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New proton radiation trial aims to extend survival in advanced cancer patients
Disease control Recruiting nowThis study tests if a precise type of proton radiation (pCSI) can help people with breast or lung cancer that has spread to the fluid-filled space around the brain and spinal cord live longer than standard x-ray radiation. About 115 participants will be randomly assigned to one o…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Spinal immunotherapy injection shows promise for tough brain cancers
Disease control Recruiting nowThis early-phase study tests a combination of two ways to give the immunotherapy drug nivolumab: through a vein and directly into the fluid around the spine. It is for people with melanoma or lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal di…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Brain metastases trial tests Split-Dose radiation for better tumor control
Symptom relief Recruiting nowThis study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 26, 2026 04:23 UTC
-
Smarter radiation: new study aims to cut lung cancer treatment side effects
Symptom relief Recruiting nowThis study tests a smarter way to give radiation to people with lung cancer. Normally, the radiation plan is made before treatment starts, but tumors can shrink during treatment, which may expose healthy tissue to unnecessary radiation. In this study, the radiation plan is update…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated May 26, 2026 04:23 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 03:56 UTC
-
Lung cancer Patients' sleep troubles under the microscope
Knowledge-focused Recruiting nowThis study looks at how often people with metastatic non-small cell lung cancer have trouble sleeping. Researchers will use a simple questionnaire to measure insomnia severity. The goal is to understand how common this sleep problem is in this group, which can help improve future…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 04:19 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 04:12 UTC
-
Can a simple scan predict lung cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at how PET/CT scans change during chemoimmunotherapy and radiation in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 participants who have not yet…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 26, 2026 03:55 UTC